Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease Save
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.
The study included patients drawn from a general practice database (IQVIA Medical Database) between 2000 and 2023, and included adults over age 40 years with both gout and CKD stage 3 who were treated with urate-lowering therapy (ULT). Renal outcomes included progression to severe or end-stage kidney disease. The SUA target was <6 mg/dL.
The study included 14 792 participants (mean age, 73.1 years; 62% men). Overall the 5-year risk of severe or end-stage kidney disease was 10.3% for those with an SUA < 6 mg/dl compared to 12.7% for those who did not achieve target (HR 0.89, 95%CI 0.80 to 0.98).
These findings support optimizing ULT to achieve target serum urate levels when treating patients with gout and impaired kidney function.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.